{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:03:13Z","timestamp":1793138593858,"version":"4.5.0"},"reference-count":262,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 HL 146991-01"],"award-info":[{"award-number":["K08 HL 146991-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["18059"],"award-info":[{"award-number":["18059"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T05:39:35Z","timestamp":1607578775000},"page":"464-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":718,"title":["Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs"],"prefix":"10.1016","volume":"29","author":[{"given":"Jerry R.","family":"Mendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiah A.","family":"Al-Zaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Goodspeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanford L.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon E.","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey A.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Salabarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-9195","authenticated-orcid":false,"given":"Jacques P.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.12.007_bib1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ymthe.2020.12.007_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.12.007_bib5","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib6","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldk\u00f6tter","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib10","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nbt.1610","article-title":"Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN","volume":"28","author":"Foust","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/hmg\/ddq514","article-title":"Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice","volume":"20","author":"Dominguez","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pediatrneurol.2019.05.005","article-title":"Impact of Age and Motor Function in a Phase 1\/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy","volume":"98","author":"Lowes","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib267","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JND-190403","article-title":"AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort","volume":"6","author":"Al-Zaidy","year":"2019","journal-title":"Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib268","doi-asserted-by":"crossref","first-page":"e20200729","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2020.12.007_bib16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2020.167","article-title":"Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology","volume":"31","author":"Hordeaux","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.12.007_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90344-5","article-title":"Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage","volume":"80","author":"Campbell","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2020.12.007_bib19","first-page":"195","article-title":"The natural history of Duchenne muscular dystrophy: a caveat for therapeutic trials","volume":"106","author":"Brooke","year":"1981","journal-title":"Trans. Am. Neurol. Assoc."},{"key":"10.1016\/j.ymthe.2020.12.007_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pediatrneurol.2014.08.002","article-title":"Gene therapy for muscular dystrophy: moving the field forward","volume":"51","author":"Al-Zaidy","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib23","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.12.007_bib25","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","article-title":"Clinical development on the frontier: gene therapy for duchenne muscular dystrophy","volume":"20","author":"Asher","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1152\/japplphysiol.01106.2010","article-title":"Evidence for impaired neurovascular transmission in a murine model of Duchenne muscular dystrophy","volume":"110","author":"Bagher","year":"2011","journal-title":"J.\u00a0Appl. Physiol. (1985)"},{"key":"10.1016\/j.ymthe.2020.12.007_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng0696-175","article-title":"A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast","volume":"13","author":"Laporte","year":"1996","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib30","doi-asserted-by":"crossref","first-page":"15060","DOI":"10.1073\/pnas.212498399","article-title":"The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice","volume":"99","author":"Buj-Bello","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib31","doi-asserted-by":"crossref","first-page":"18763","DOI":"10.1073\/pnas.0900705106","article-title":"T-tubule disorganization and defective excitation-contraction coupling in muscle fibers lacking myotubularin lipid phosphatase","volume":"106","author":"Al-Qusairi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.26018","article-title":"A multicenter, retrospective medical record review of X-linked myotubular myopathy: The recensus study","volume":"57","author":"Beggs","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2020.12.007_bib33","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/hmg\/ddt038","article-title":"Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle","volume":"22","author":"Joubert","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib34","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1093\/hmg\/ddn112","article-title":"AAV-mediated intramuscular delivery of myotubularin corrects the myotubular myopathy phenotype in targeted murine muscle and suggests a function in plasma membrane homeostasis","volume":"17","author":"Buj-Bello","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib35","doi-asserted-by":"crossref","first-page":"220ra10","DOI":"10.1126\/scitranslmed.3007523","article-title":"Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy","volume":"6","author":"Childers","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2017.02.004","article-title":"Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in Dogs","volume":"25","author":"Mack","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/mus.25658","article-title":"Long-term effects of systemic gene therapy in a canine model of myotubular myopathy","volume":"56","author":"Elverman","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2020.12.007_bib38","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","article-title":"X-linked myotubular myopathy: A prospective international natural history study","volume":"92","author":"Annoussamy","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-180422","article-title":"Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer\u2019s Disease: Are We There Yet?","volume":"65","author":"Raikwar","year":"2018","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib40","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1523\/JNEUROSCI.10-12-03801.1990","article-title":"Mouse nerve growth factor prevents degeneration of axotomized basal forebrain cholinergic neurons in the monkey","volume":"10","author":"Koliatsos","year":"1990","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2020.12.007_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/329065a0","article-title":"Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor","volume":"329","author":"Fischer","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.12.007_bib42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jalz.2013.09.004","article-title":"A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer\u2019s disease","volume":"10","author":"Rafii","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2020.12.007_bib43","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib44","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0140-6736(07)60982-9","article-title":"Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson\u2019s disease: an open label, phase I trial","volume":"369","author":"Kaplitt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","article-title":"AAV2-GAD gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial","volume":"10","author":"LeWitt","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib46","doi-asserted-by":"crossref","first-page":"e90133","DOI":"10.1172\/jci.insight.90133","article-title":"Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson\u2019s disease","volume":"2","author":"Niethammer","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.12.007_bib47","doi-asserted-by":"crossref","first-page":"eaau0713","DOI":"10.1126\/scitranslmed.aau0713","article-title":"Gene therapy reduces Parkinson\u2019s disease symptoms by reorganizing functional brain connectivity","volume":"10","author":"Niethammer","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib48","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","article-title":"Results from a phase I safety trial of hAADC gene therapy for Parkinson disease","volume":"70","author":"Eberling","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib49","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib50","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.25450","article-title":"Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson\u2019s disease","volume":"85","author":"Christine","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib52","doi-asserted-by":"crossref","first-page":"165ra163","DOI":"10.1126\/scitranslmed.3003454","article-title":"Long-term follow-up after gene therapy for canavan disease","volume":"4","author":"Leone","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6","article-title":"Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease","volume":"48","author":"Leone","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib54","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1089\/104303402760128612","article-title":"Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain","volume":"13","author":"Janson","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00401-017-1784-9","article-title":"Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy","volume":"135","author":"von Jonquieres","year":"2018","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib56","first-page":"1","article-title":"Natural History of Aromatic L-Amino Acid Decarboxylase Deficiency in Taiwan","volume":"40","author":"Hwu","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2020.12.007_bib57","doi-asserted-by":"crossref","first-page":"134ra61","DOI":"10.1126\/scitranslmed.3003640","article-title":"Gene therapy for aromatic L-amino acid decarboxylase deficiency","volume":"4","author":"Hwu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","article-title":"Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial","volume":"1","author":"Chien","year":"2017","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.ymthe.2020.12.007_bib59","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/brain\/awy331","article-title":"Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency","volume":"142","author":"Kojima","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2020.12.007_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10048-019-00596-z","article-title":"Giant axonal neuropathy: a multicenter retrospective study with genotypic spectrum expansion","volume":"21","author":"Echaniz-Laguna","year":"2020","journal-title":"Neurogenetics"},{"key":"10.1016\/j.ymthe.2020.12.007_bib61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.omtm.2018.02.005","article-title":"Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy","volume":"9","author":"Bailey","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib62","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1227\/NEU.0b013e318217217e","article-title":"T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery","volume":"69","author":"Richardson","year":"2011","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ymthe.2020.12.007_bib64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/hum.2011.162","article-title":"Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum","volume":"23","author":"San Sebastian","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib65","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib66","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/gt.2012.101","article-title":"Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates","volume":"20","author":"Gray","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib67","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib68","doi-asserted-by":"crossref","first-page":"146832","DOI":"10.1016\/j.brainres.2020.146832","article-title":"Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies","volume":"1739","author":"Bailey","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.ymthe.2020.12.007_bib69","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib70","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib71","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib72","doi-asserted-by":"crossref","first-page":"15112","DOI":"10.1073\/pnas.0807027105","article-title":"Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics","volume":"105","author":"Cideciyan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib74","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib75","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.preteyeres.2010.04.002","article-title":"Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy","volume":"29","author":"Cideciyan","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.12.007_bib76","doi-asserted-by":"crossref","first-page":"a017285","DOI":"10.1101\/cshperspect.a017285","article-title":"The Status of RPE65 Gene Therapy Trials: Safety and Efficacy","volume":"5","author":"Pierce","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib77","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jgm.2768","article-title":"Adeno-associated virus 8-mediated gene therapy for choroideremia: preclinical studies in in\u00a0vitro and in\u00a0vivo models","volume":"16","author":"Black","year":"2014","journal-title":"J.\u00a0Gene Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib78","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/hmg\/ddq136","article-title":"Gene therapy rescues cone function in congenital achromatopsia","volume":"19","author":"Kom\u00e1romy","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib79","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1089\/hum.2018.076","article-title":"Six Years and Counting: Restoration of Photopic Retinal Function and Visual Behavior Following Gene Augmentation Therapy in a Sheep Model of CNGA3 Achromatopsia","volume":"29","author":"Ofri","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib80","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/mt.2010.149","article-title":"Restoration of cone vision in the CNGA3-\/- mouse model of congenital complete lack of cone photoreceptor function","volume":"18","author":"Michalakis","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib81","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1093\/hmg\/ddr218","article-title":"Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy","volume":"20","author":"Carvalho","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib82","doi-asserted-by":"crossref","first-page":"E5844","DOI":"10.1073\/pnas.1509914112","article-title":"Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease","volume":"112","author":"Beltran","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib83","doi-asserted-by":"crossref","first-page":"E8547","DOI":"10.1073\/pnas.1805055115","article-title":"Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector","volume":"115","author":"Cideciyan","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2020.12.007_bib85","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib87","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I\/IIa Trial by Intravitreal Delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib88","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and Safety of Retinal Gene Therapy Using Adeno-Associated Virus Vector for Patients With Choroideremia: A Randomized Clinical Trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib89","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","article-title":"Changes in Retinal Sensitivity after Gene Therapy in Choroideremia","volume":"40","author":"Fischer","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.12.007_bib90","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","article-title":"Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial","volume":"138","author":"Fischer","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1615\/CritRevImmunol.v22.i1.20","article-title":"Immune privilege in the anterior chamber of the eye","volume":"22","author":"Niederkorn","year":"2002","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08830180212066","article-title":"Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy","volume":"21","author":"Stein-Streilein","year":"2002","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib93","doi-asserted-by":"crossref","first-page":"100827","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: Early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.ymthe.2020.12.007_bib94","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ymthe.2020.12.007_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-020-00216-1","article-title":"Intraoperative optical coherence tomographic findings in patients undergoing subretinal gene therapy surgery","volume":"6","author":"Vasconcelos","year":"2020","journal-title":"Int. J. Retina Vitreous"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib96","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical Technique for Subretinal Gene Therapy in Humans with Inherited Retinal Degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.ymthe.2020.12.007_bib97","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib98","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib99","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib100","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib101","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/hum.2019.337","article-title":"Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy","volume":"31","author":"Song","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib103","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1074\/mcp.M700054-MCP200","article-title":"The proteome of the mouse photoreceptor sensory cilium complex","volume":"6","author":"Liu","year":"2007","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymthe.2020.12.007_bib104","first-page":"756","article-title":"Efficiency of lentiviral transduction during development in normal and rd mice","volume":"12","author":"Pang","year":"2006","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/hum.2013.009","article-title":"Vesicular stomatitis virus glycoprotein- and Venezuelan equine encephalitis virus-derived glycoprotein-pseudotyped lentivirus vectors differentially transduce corneal endothelium, trabecular meshwork, and human photoreceptors","volume":"25","author":"Lipinski","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib106","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/hgtb.2013.212","article-title":"Dual adeno-associated virus vectors result in efficient in\u00a0vitro and in\u00a0vivo expression of an oversized gene, MYO7A","volume":"25","author":"Dyka","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.ymthe.2020.12.007_bib107","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib108","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/hmg\/dds421","article-title":"Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants","volume":"22","author":"Jacobson","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ajo.2019.10.019","article-title":"GUCY2D-Associated Leber Congenital Amaurosis: A Retrospective Natural History Study in Preparation for Trials of Novel Therapies","volume":"210","author":"Bouzia","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib110","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ymthe.2020.04.002","article-title":"Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy","volume":"28","author":"Boye","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib111","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ajo.2006.05.045","article-title":"Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment","volume":"142","author":"Olsen","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib112","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ymthe.2020.12.007_bib113","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.12.007_bib114","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.007_bib115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib116","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib117","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1167\/iovs.17-22233","article-title":"A Subretinal Cell Delivery Method via Suprachoroidal Access in Minipigs: Safety and Surgical Outcomes","volume":"59","author":"de Smet","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.12.007_bib118","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib119","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2020.12.007_bib120","doi-asserted-by":"crossref","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In\u00a0vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib121","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib122","doi-asserted-by":"crossref","first-page":"e135112","DOI":"10.1172\/jci.insight.135112","article-title":"In\u00a0vivo-directed evolution of adeno-associated virus in the primate retina","volume":"5","author":"Byrne","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.12.007_bib123","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib124","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/gt.2014.31","article-title":"Retinoschisin gene therapy in photoreceptors, M\u00fcller glia or all retinal cells in the Rs1h-\/- mouse","volume":"21","author":"Byrne","year":"2014","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib126","doi-asserted-by":"crossref","first-page":"e62097","DOI":"10.1371\/journal.pone.0062097","article-title":"Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors","volume":"8","author":"Kay","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.12.007_bib127","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/humc.2015.076","article-title":"Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-CB-hRS1, a Recombinant Adeno-Associated Virus Vector Expressing Retinoschisin","volume":"26","author":"Ye","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/humc.2015.164","article-title":"Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia","volume":"27","author":"Ye","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2-ND4 Gene Therapy for Leber Hereditary Optic Neuropathy","volume":"125","author":"Vignal","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune Response and Intraocular Inflammation in Patients With Leber Hereditary Optic Neuropathy Treated With Intravitreal Injection of Recombinant Adeno-Associated Virus 2 Carrying the ND4 Gene: A Secondary Analysis of a Phase 1\/2 Clinical Trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib132","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/mt.2010.258","article-title":"Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration","volume":"19","author":"Maclachlan","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib133","series-title":"Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results, August 10, 2020","year":"2020"},{"key":"10.1016\/j.ymthe.2020.12.007_bib134","series-title":"Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD, April 15, 2019","year":"2019"},{"key":"10.1016\/j.ymthe.2020.12.007_bib135","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib136","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib137","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing\u201d empty viral particles\u201d on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib138","first-page":"144","article-title":"SHP648: an analysis of bleeding rates and Factor IX Consumption in the Phase I\/II BAX 335 Gene Therapy Trial in Subjects with Hemophilia B","volume":"2017","author":"Chapin","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib139","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib140","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood-2019-122535","article-title":"Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B","volume":"134","author":"Miesbach","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib141","series-title":"Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate\/Severe to Severe Hemophilia B. Last updated: November 14, 2018. NCT02618915","year":"2018"},{"key":"10.1016\/j.ymthe.2020.12.007_bib142","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/asheducation-2017.1.587","article-title":"Hemophilia gene therapy comes of age","volume":"2017","author":"George","year":"2017","journal-title":"Hematology (Am. Soc. Hematol. Educ. Program)"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib143","article-title":"A novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe Hemophilia B (HB) patients (B-AMAZE study)","volume":"4","author":"Chowdary","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib144","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib145","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2019-124091","article-title":"Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year","volume":"134","author":"George","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib146","first-page":"20","article-title":"Therapeutic human Factor IX (hFIX) activity after single treatment with AMT-060 (AAV5-hFIX) or AMT-061 (AAV5-Padua hFIX) in Hemophilia B patients with pre-existing anti-AAV5 humoral immunity","volume":"26","author":"Majowicz","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib147","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-Factor VIII Gene Transfer in Severe Hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib148","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib149","series-title":"World Federation of Hemophilia Virtual Summit Update. First-in-human four-year follow-up study of durable therapeutic efficacy and safety: AAV gene therapy with Valoctocogene Roxaparvovec for severe hemophilia A, June 17, 2020","year":"2020"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib150","first-page":"OC 03.5","article-title":"Phase I\/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A","volume":"4","author":"George","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib151","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2019-122143","article-title":"Updated Follow-up of the Alta Study, a Phase 1\/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy","volume":"134","author":"Konkle","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib153","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2018-99-118256","article-title":"GO-8: Preliminary Results of a Phase I\/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib154","first-page":"408","article-title":"First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results","volume":"28","author":"Pipe","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib155","series-title":"Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A. Last updated: May 6, 2020. NCT03818763","year":"2020"},{"key":"10.1016\/j.ymthe.2020.12.007_bib156","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2012-05-432591","article-title":"Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice","volume":"120","author":"Cantore","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib157","doi-asserted-by":"crossref","first-page":"277ra28","DOI":"10.1126\/scitranslmed.aaa1405","article-title":"Liver-directed lentiviral gene therapy in a dog model of hemophilia B","volume":"7","author":"Cantore","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib158","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1038\/ncomms3773","article-title":"Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A","volume":"4","author":"Du","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.12.007_bib159","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.007_bib160","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1182\/blood-2010-06-293308","article-title":"In\u00a0vivo efficacy of platelet-delivered, high specific activity factor VIII variants","volume":"116","author":"Greene","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib161","first-page":"935","article-title":"Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice","volume":"118","author":"Follenzi","year":"2008","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.007_bib162","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib163","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/hum.2014.2540","article-title":"Our journey to successful gene therapy for hemophilia B","volume":"25","author":"Nathwani","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib164","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib166","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib167","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","article-title":"Murine coagulation factor VIII is synthesized in endothelial cells","volume":"123","author":"Everett","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib168","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1182\/blood-2009-02-206979","article-title":"Extrahepatic factor VIII production in transplant recipient of hemophilia donor liver","volume":"113","author":"Madeira","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib169","doi-asserted-by":"crossref","first-page":"6461","DOI":"10.1073\/pnas.79.21.6461","article-title":"Isolation and characterization of a cDNA coding for human factor IX","volume":"79","author":"Kurachi","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib170","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib171","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib172","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","article-title":"Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project","volume":"129","author":"Manco-Johnson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib173","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.14072","article-title":"Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study","volume":"174","author":"Schrijvers","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib174","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/hae.12683","article-title":"Transition considerations for extended half-life factor products","volume":"21","author":"Croteau","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib179","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2020.12.007_bib180","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib181","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.007_bib182","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ng1179","article-title":"AAV serotype 2 vectors preferentially integrate into active genes in mice","volume":"34","author":"Nakai","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib183","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib184","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/j.1572-0241.2003.07678.x","article-title":"The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?","volume":"98","author":"Goodgame","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib185","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2020.12.007_bib186","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection","volume":"14","author":"Lu","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib187","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/hae.13668","article-title":"Incidence and risk factors for hepatocellular cancer in individuals with haemophilia: A National Inpatient Sample Study","volume":"25","author":"Thalappillil","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib188","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","article-title":"Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B","volume":"28","author":"George","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib189","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1182\/blood.V84.12.4214.bloodjournal84124214","article-title":"Role of the B domain for factor VIII and factor V expression and function","volume":"84","author":"Pittman","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1432-1033.1995.tb20776.x","article-title":"Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization","volume":"232","author":"Lind","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ymthe.2020.12.007_bib191","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-0037-1612910","article-title":"Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ","volume":"85","author":"Sandberg","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib192","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in\u00a0vivo functional characterization of B-domain-deleted factor VIII","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib193","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib194","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib195","doi-asserted-by":"crossref","first-page":"e128683","DOI":"10.1172\/jci.insight.128683","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.12.007_bib196","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors","volume":"328","author":"Lusher","year":"1993","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib197","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib198","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib199","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2516.2009.02027.x","volume":"15","author":"Recht","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib200","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1111\/jth.12335","article-title":"Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression","volume":"11","author":"Xi","year":"2013","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib201","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy","volume":"12","author":"Samelson-Jones","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib202","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib203","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib204","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1182\/blood-2012-06-440123","article-title":"The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy","volume":"120","author":"Finn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib205","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib206","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/hae.13717","article-title":"The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors","volume":"25","author":"Ragni","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib207","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1038\/mtm.2015.53","article-title":"Targeted approaches to induce immune tolerance for Pompe disease therapy","volume":"3","author":"Doerfler","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib208","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2020.12.007_bib209","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2020.12.007_bib210","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib211","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nm.4149","article-title":"A rapid pro-hemostatic approach to overcome direct oral anticoagulants","volume":"22","author":"Thalji","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib212","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02383.x","article-title":"Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels","volume":"17","author":"den Uijl","year":"2011","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib213","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2018-99-119616","article-title":"Activity of a FIX-Padua Transgene Product in Commonly Used FIX:C One-Stage and Chromogenic Assay Systems Following PF-06838435 (SPK-9001) Gene Delivery","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib214","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/hae.12962","article-title":"Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII","volume":"22","author":"Kitchen","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.ymthe.2020.12.007_bib215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtm.2020.05.033","article-title":"Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice","volume":"18","author":"Zou","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib216","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib217","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.12.007_bib218","series-title":"Hemophilia B Gene Therapy With AAV8 Vector. Last updated March 12, 2019. NCT01620801","year":"2020"},{"key":"10.1016\/j.ymthe.2020.12.007_bib219","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib220","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib221","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2019-126007","article-title":"Long-Term AAV-Mediated Factor VIII Expression in Nine Hemophilia A Dogs: A 10 Year Follow-up Analysis on Durability, Safety and Vector Integration","volume":"134","author":"Nguyen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib222","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib223","doi-asserted-by":"crossref","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib224","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.12.007_bib225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omtm.2019.05.009","article-title":"Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs","volume":"14","author":"Majowicz","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib226","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/humc.2016.048","article-title":"AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees","volume":"27","author":"Calcedo","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib227","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/hum.2019.143","article-title":"Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome","volume":"30","author":"Aronson","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib228","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1093\/nar\/gkv1121","article-title":"Highly efficient homology-driven genome editing in human T\u00a0cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.12.007_bib229","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib230","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib231","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41572-018-0031-6","article-title":"Lysosomal storage disorders","volume":"4","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2020.12.007_bib232","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2020.12.007_bib233","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib234","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","article-title":"Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy","volume":"41","author":"van der Meijden","year":"2018","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib235","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib236","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib237","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/1566524024605789","article-title":"Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)","volume":"2","author":"Raben","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ymthe.2020.12.007_bib238","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.24433","article-title":"Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease","volume":"78","author":"Todd","year":"2015","journal-title":"Ann. Neurol."},{"issue":"R1","key":"10.1016\/j.ymthe.2020.12.007_bib239","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","article-title":"Pompe disease gene therapy","volume":"20","author":"Byrne","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib241","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib242","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib243","doi-asserted-by":"crossref","first-page":"14033","DOI":"10.1038\/mtm.2014.33","article-title":"B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study","volume":"1","author":"Corti","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib244","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.24444","article-title":"Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction","volume":"51","author":"Corti","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2020.12.007_bib245","series-title":"Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1\/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy. August 7, 2018","year":"2018"},{"key":"10.1016\/j.ymthe.2020.12.007_bib246","series-title":"First Patient Dosed with Gene Therapy in Phase 1\/2 Study of ACTUS-101 in Patients with Pompe Disease. January 22, 2019","year":"2019"},{"issue":"Suppl 1","key":"10.1016\/j.ymthe.2020.12.007_bib247","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S1353-8020(13)70034-8","article-title":"Niemann-Pick\u2019s and Gaucher\u2019s diseases","volume":"20","author":"Stern","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ymthe.2020.12.007_bib248","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/hum.1996.7.2-231","article-title":"Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease. A phase I study","volume":"7","author":"Dunbar","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib249","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1073\/pnas.87.6.2334","article-title":"Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease","volume":"87","author":"Fink","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.12.007_bib250","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1089\/hum.1998.9.17-2629","article-title":"Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in\u00a0vivo detection of transduced cells without myeloablation","volume":"9","author":"Dunbar","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib251","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/mt.2015.16","article-title":"Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice","volume":"23","author":"Dahl","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib252","first-page":"4","article-title":"A Review of Fabry Disease","volume":"23","author":"Chan","year":"2018","journal-title":"Skin Therapy Lett."},{"key":"10.1016\/j.ymthe.2020.12.007_bib253","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and Investigational Therapeutics for Fabry Disease","volume":"5","author":"Felis","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2020.12.007_bib254","first-page":"109","article-title":"Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy","volume":"5","author":"Nicholls","year":"2012","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymthe.2020.12.007_bib255","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib256","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s10038-018-0537-5","article-title":"Gene therapy for lysosomal storage diseases and peroxisomal diseases","volume":"64","author":"Ohashi","year":"2019","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.12.007_bib257","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.omtm.2017.05.003","article-title":"Lentivector Iterations and Pre-Clinical Scale-Up\/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease","volume":"5","author":"Huang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.12.007_bib258","series-title":"Sangamo Announces FDA Acceptance of IND Application for ST-920 Gene Therapy Candidate for Fabry Disease. February 20, 2019","year":"2019"},{"key":"10.1016\/j.ymthe.2020.12.007_bib259","series-title":"Freeline receives Orphan Drug Designation from the European Commission for FLT190 for the treatment of Fabry Disease. May 4, 2020","year":"2020"},{"key":"10.1016\/j.ymthe.2020.12.007_bib260","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib261","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2020.12.007_bib262","doi-asserted-by":"crossref","first-page":"165571","DOI":"10.1016\/j.bbadis.2019.165571","article-title":"Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses","volume":"1866","author":"Butz","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib263","doi-asserted-by":"crossref","first-page":"165570","DOI":"10.1016\/j.bbadis.2019.165570","article-title":"Pathomechanisms in the neuronal ceroid lipofuscinoses","volume":"1866","author":"Nelvagal","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ymthe.2020.12.007_bib264","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases - clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2020.12.007_bib265","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.12.007_bib266","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","article-title":"Gene Therapy Corrects Brain and Behavioral Pathologies in CLN6-Batten Disease","volume":"27","author":"Cain","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162030664X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162030664X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:06:12Z","timestamp":1778616372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162030664X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":262,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S152500162030664X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}]}}